公开(公告)号：US20240360222A1

公开(公告)日：2024-10-31

申请号：US18662493

申请日：2024-05-13

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K19/00 ,  C12N5/10 ,  C12N15/09 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180193451A1

公开(公告)日：2018-07-12

申请号：US15741225

申请日：2016-06-30

Applicant: OSAKA UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Atsushi KUMANOGOH ,  Ryusuke OMIYA ,  Hiroyuki TSUNODA ,  Takeshi BABA ,  Sachiyo SUZUKI ,  Yuri TERANISHI

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/46 ,  C12N15/09

Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.

公开(公告)号：US20220064287A1

公开(公告)日：2022-03-03

申请号：US17527681

申请日：2021-11-16

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH

IPC: C07K16/28 ,  C07K16/30 ,  C07K19/00 ,  A61P35/00 ,  C12N15/62

Abstract: Provided is an antibody effective in treating tumors and the like. The antibody recognizes an epitope that contains an N-glycosylation site of human CD98hc and that is exposed by inhibiting N-linked glycosylation.

公开(公告)号：US20210113594A1

公开(公告)日：2021-04-22

申请号：US16979610

申请日：2019-03-13

Applicant: OSAKA UNIVERSITY

Inventor： Kota IWAHORI ,  Hisashi WADA ,  Yuki NOGUCHI ,  Atsushi KUMANOGOH

IPC: A61K31/65 ,  A61P37/04 ,  A61P35/04 ,  A61K45/06

Abstract: The present invention provides a less expensive immunotherapy drug for tumor.
Tumor immunity can be activated by at least one member selected from the group consisting of tetracycline-based compounds and pharmaceutically acceptable salts thereof.

公开(公告)号：US20210003571A1

公开(公告)日：2021-01-07

申请号：US17006374

申请日：2020-08-28

Applicant: OSAKA UNIVERSITY

Inventor： Atsushi KUMANOGOH

IPC: G01N33/566 ,  C07K16/18 ,  C07K16/28 ,  G01N33/53

Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

公开(公告)号：US20140349311A1

公开(公告)日：2014-11-27

申请号：US14258617

申请日：2014-04-22

Applicant: OSAKA UNIVERSITY

Inventor： Atsushi KUMANOGOH

IPC: G01N33/566 ,  G01N33/53

Abstract: Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.

Abstract translation: 公开了用于治疗细胞免疫疾病的治疗剂，其包含抑制Sema3A与神经蛋白-1 / Plexin-A1异型受体结合的物质作为活性成分。 该物质包括例如Sema3A中和抗体，Neuropilin-1中和抗体或可溶性神经蛋白-1或其衍生物。 还公开了利用由Neuropilin-1，Plexin-A1和Sema3A的相互作用产生的信号作为标记来筛选治疗细胞免疫疾病的治疗剂的方法。

公开(公告)号：US20200283533A1

公开(公告)日：2020-09-10

申请号：US16808451

申请日：2020-03-04

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  C12N5/10 ,  C12N15/09 ,  A61K39/00 ,  C07K19/00 ,  A61P35/00

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180230216A1

公开(公告)日：2018-08-16

申请号：US15751574

申请日：2016-08-02

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH ,  Junichi TAKAGI

IPC: C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C12N15/09 ,  C12N5/10

CPC classification number: C07K16/2839 ,  A61K35/17 ,  A61K39/0011 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61P35/00 ,  C07K16/30 ,  C07K19/00 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/10 ,  C12N15/09

Abstract: Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

公开(公告)号：US20180230212A1

公开(公告)日：2018-08-16

申请号：US15751717

申请日：2016-08-09

Applicant: OSAKA UNIVERSITY

Inventor： Naoki HOSEN ,  Haruo SUGIYAMA ,  Atsushi KUMANOGOH

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/62 ,  C07K19/00

CPC classification number: C07K16/28 ,  A61K38/1709 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2896 ,  C07K16/3061 ,  C07K19/00 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/62

Abstract: Provided is an antibody effective in the treatment of tumors and the like. An antibody that includes an N-type glycosylation site of human CD98hc and recognizes an epitope exposed by inhibition of N-type glycosylation modification.